Search in:

Expert Opinion on Therapeutic Targets Volume 12, 2008 - Issue 7

Submit an article Journal homepage

234

Views

CrossRef citations to date

Altmetric

Review

From hyperglycemia to AGE-RAGE interaction on the cell surface: A dangerous metabolic route for diabetic patients

José Augusto Nogueira-Machado Hospital Santa Casa de Belo Horizonte, Núcleo de Pesquisa e Pós-Graduação, Avenue Francisco Sales, 1111, 30250-330, Belo Horizonte, MG, Brazil +55 31 3238 88 38; +55 31 3238 88 38; [email protected]

Miriam Martins Chaves Instituto de Ciências Biológicas da Universidade Federal de Minas Gerais, Departamento de Bioquímica e Imunologia, Brazil

Pages 871-882 | Published online: 13 Jun 2008

Cite this article
https://doi.org/10.1517/14728222.12.7.871

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Thomas E, Lin YS, Dagher Z, et al. Hyperglycemia and insulin resistance: possible mechanism. Ann NY Acad Sci 2002;967:43-8
PubMedGoogle Scholar
Srivastva AK. High glucose-induced activation of protein kinase signalling pathway in vascular smooth muscle cells: a potential role in the pathogenesis of vascular dysfunction in diabetes. Int J Mol Med 2002;9:85-9
PubMedGoogle Scholar
Nogueira-Machado JA, Lima E Silva FC, Lima E Silva R, et al. Effect in vitro of cyclic nucleotide-elevating agents on nitric oxide production by human granulocytes from type 2 diabetic patients. Diabetes Metab 2002;28:45-50
PubMedGoogle Scholar
Nogueira-Machado JA, Lima E Silva FC, Cunha EP, et al. Modulation of the production of reactive oxygen species (ROS) by cAMP-elevating agents in granulocytes from diabetic patients: a Akt/PKB-dependent phenomenon. Diabetes Metab 2006;32:331-5
PubMedGoogle Scholar
Nogueira-Machado JA, Lima E Silva FC, Medina LO, et al. Modulation of the reactive oxygen species (ROS) generation mediated by cyclic AMP-elevating agents or interleukin 10 in granulocytes from type 2 diabetic patients (NIDDM): a PKA-independent phenomenon. Diabetes Metab 2003;29:533-7
PubMedGoogle Scholar
Hii H, Daisuke K, King GL. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J Mol Med 1998;76:21-31
PubMedGoogle Scholar
Das Evcimen N, King GL. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res 2007;55:498-510
PubMed Web of Science ®Google Scholar
Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1998;19:257-67
Google Scholar
Shikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemia damage. Nature 2000;404:787-90
PubMedGoogle Scholar
Ques-Vivar J, Kalyanaraman B, Martasek P, et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci USA 1998;95:9220-5
PubMedGoogle Scholar
Agopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alteration of vasomotor tone. J Clin Invest 1996;97:1916-23
PubMedGoogle Scholar
Nes SA, O'Donnell VB, Wood J D, et al. Expression of phagocyte NADPH oxidase components in human endothelial cells. Am J Physiol 1996;271:H1626-34
Google Scholar
Pearson C, Ruef F, Madamanchi NR, et al. Stimulation of a vascular smooth muscle cell NADPH oxidase by thrombin: evidence that p47phox may participate in forming this oxidase in vitro and in vivo. J Biol Chem 1999;274:19814-22
PubMedGoogle Scholar
Suh YA, Arnold RS, Lassegue B, et al. Cell transformation by the superoxide-generating oxidase nox 1. Nature 1999;401:79-82
PubMed Web of Science ®Google Scholar
Pagano PJ, Clark JK, Cifuentes-Paganoi ME, et al. Localization of a constitutively active phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc Natl Acad Sci USA 1997;94:14483-8
PubMed Web of Science ®Google Scholar
Mohazzab-HKM, Kaminsk PM, Wolin MS. NADPH oxireductase is a major source of superoxide anion in bovine coronary artery endothelium. Am J Physiol 1994;266:H2568-72
Google Scholar
Nyshizuka Y. Intracellular signalling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992;258:607-14
PubMedGoogle Scholar
Nishuzuka Y. Protein kinase C and lipid signalling for sustained cellular responses. FASEB J 1995;9:484-96
PubMedGoogle Scholar
Bursell SE, Takagi C, Clermont AC, et al. Specific retinal diacylglycerol and protein kinase C beta isoform modulation mimics abnormal retinal hemodynamics in diabetic rats. Invest Ophthalmol Vis Sci 1997;38:2711-9
PubMed Web of Science ®Google Scholar
Carrasco S, Mérida I. Diacylglycerol, when simplicity becomes complex. Trends Biochem Sci 2007;32:27-36
PubMed Web of Science ®Google Scholar
Risso A, Mercuri F, Quagliaro L, et al. Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. Am J Physiol 2001;87:1123-32
Google Scholar
Inoguchi T, Battan R, Handler E, et al. Preferential elevation of protein kinase C isoform β II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci USA 1992;89:11059-63
PubMed Web of Science ®Google Scholar
Craven PA, Davidson CM, Derubertis FR. Increase in diacylglycerol mass in isolated glomeruli by glucose from de novo synthesis of glycerolipids. Diabetes 1990;39:667-74
PubMed Web of Science ®Google Scholar
Xia P, Inoguchi T, Kern TS, et al. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes 1994;43:1122-9
PubMed Web of Science ®Google Scholar
Quagliaro L, Piconi L, Assaloni R, et al. Intermittent high glucose enhances apoptosis related to oxidative stress in human vein endothelial cells – the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 2003;52:2795-804
PubMed Web of Science ®Google Scholar
De Chaffoy DE, Courcelles D, Roevens P, et al. The role of endogenously formed diacylglycerol in the propagation and termination of platelet activation. J Biol Chem 1989;264:3274-85
PubMedGoogle Scholar
Choi CS, Savage DB, Kulkarni A, et al. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with anti-sense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J Biol Chem 2007;282:22678-88
PubMed Web of Science ®Google Scholar
Delarue J, Magnan C. Free fatty acids and insulin resistance. Curr Opin Clin Nutr Metab Care 2007;10:142-8
PubMed Web of Science ®Google Scholar
Kin U, Tsilimingas N, Wendt M, Munzel T. Mechanism underlying endothelial dysfunction in diabetes mellitus: therapeutic implication. Treat Endocrinol 2003;2:293-304
PubMedGoogle Scholar
Tuttle KR, Anderson PW. A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C β inhibition. Am J Kidney Dis 2003;42:456-65
PubMed Web of Science ®Google Scholar
Long GE. Treatment of diabetic nephropathy with protein kinase C subtype beta inhibitor. Dev Ophthalmol 2007;39:157-65
PubMedGoogle Scholar
Frank RN. Potential new medical therapies for diabetic retinopathy: Protein kinase inhibitor. Am J Ophthalmol 2002;133:693-8
PubMed Web of Science ®Google Scholar
Joy SV, Scates AC, Bearelly S, et al. Ruboxistaurin, a protein kinase C β inhibitor, as an emerging treatment for diabetes microvascular complications. Ann Pharmacother 2005;39:1693-9
PubMed Web of Science ®Google Scholar
Adis International Limited. Ruboxistaurin: LY 333531. Drugs R&D 2007;8:193-9
PubMedGoogle Scholar
Avignon A, Sultan A. PKC–B inhibition: a new therapeutic approach for diabetic complications. Diabetes Metab 2006;32:205-13
PubMed Web of Science ®Google Scholar
Wan Y. Termination of development of ruboxistaurin (Arxxant) for diabetic microvascular complications. Available online from: http://www.nelm.nhs.uk/Record%20Viewing/viewRecord.aspx?id=584600 [Last accessed 22 May 2008]
Google Scholar
Griending KK, Sorescu D, Ushio-Fukai M. NADPH-oxidase: role in cardiovascular biology and disease. Circ Res 2000;86:494-501
PubMedGoogle Scholar
Vignais PV. The superoxide–generating NADPH-oxidase: structural aspects and activation mechanism. Cell Mol Life 2002;59:1428-59
PubMed Web of Science ®Google Scholar
Lassegue B, Clempus RE. Vascular NADPH-oxidase: specific features, expression and regulation. Am J Physiol Reg I 2003;285:R277-97
PubMed Web of Science ®Google Scholar
Tojo A, Asaba K, Onozato ML. Suppressing renal NADPH-oxidase to treat diabetic nephropathy. Expert Opin Ther Targets 2007;11:1011-8
PubMed Web of Science ®Google Scholar
Guzik TJ, Mussa S, Gastaldi D, et al. Mechanism of increased vascular superoxide production in human diabetes mellitus: role of NADPH-oxidase and endothelial nitric oxide synthase. Circulation 2002;105:1656-62
PubMed Web of Science ®Google Scholar
Gorlach A, Brandes RP, Bassus P, et al. Oxidative stress and expression of p22phox are involved in the up-regulation of tissue factor in vascular smooth muscle cells in response to activated platelets. FASEB J 2000;14:1518-28
PubMed Web of Science ®Google Scholar
De Keulenaer GW, Chappell DC, Ishizaka N, et al. Tumor necrosis factor α activates p22phox-based NADPH-oxidase in vascular smooth muscle. Biochem J 1998;329:653-7
PubMed Web of Science ®Google Scholar
Vecchione C, Arentini A, Mauno G, et al. Selective Rac-1 inhibition protects from diabetes-induced vascular injury. Circ Res 2006;98:218-25
PubMedGoogle Scholar
Vecchione C, Gentile MT, Aretini A, et al. A novel mechanism of action for statin against diabetes-induced oxidative stress. Diabetologia 2007;50:874-80
PubMed Web of Science ®Google Scholar
Benrahmoune M, Therond P, Abedinzadeh Z. The activation of superoxide radical with N-acetylcysteine. Free Radic Biol Med 2000;24:775-82
Google Scholar
Stolk J, Hiltermann TJ, Dijkman JH, et al. Characteristics of the inhibition of NADPH-oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am J Respir Cell Biol 1994;11:95-102
PubMed Web of Science ®Google Scholar
Nakayama M, Inoguchi T, Sonta T, et al. Increased expression of NADP(H) oxidase in islet of animal models of type diabetes and its improvements by an AT1 receptor antagonists. Biochem Biophys Res Commun 2005;331:927-33
Google Scholar
Brownlee M. Advanced glucosylation in diabetes and aging. Ann Rev Med 1995;46:223-34
PubMed Web of Science ®Google Scholar
Otevall A, Hulthe J, Rosengren A, et al. Autoantibodies against low-density lipoprotein and C-reactive protein are associated with diabetes and myocardial infarction in women. Clin Sci 2001;101:523-31
Google Scholar
Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications. A new perspective on an old paradigm. Diabetes 1999;48:1-9
PubMed Web of Science ®Google Scholar
Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complication. A new perspective on an old paradigm. Diabetes 1999;48:1-9
PubMed Web of Science ®Google Scholar
Corman B, Duriez M, Poitevin P, et al. Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. Proc Natl Acad Sci USA 1998;95:1301-6
PubMed Web of Science ®Google Scholar
Forbes JM, Soulis T, Thallas V, et al. Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 2001;44:108-14
PubMed Web of Science ®Google Scholar
Kass DA. Getting better without AGE: new insight into the diabetic heart. Circ Res 2003;92:704-6
PubMed Web of Science ®Google Scholar
Zhang FL, Casey PJ. Protein prenylation: molecular mechanism and functional consequences. Ann Rev Biochem 1996;65:241-69
PubMed Web of Science ®Google Scholar
Okamoto T, Yamagishi S, Inagaki Y, et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J 2002;16:1928-30
PubMed Web of Science ®Google Scholar
Degenhardt TP, Alderson NL, Arrimgton DD, et al. Pyridoxamine inhibits early renal disease and dyslipidemia in streptozotocin-diabetic-rat. Kidney Int 2002;61:939-50
PubMed Web of Science ®Google Scholar
Ahmed N, Thornalley PJ. Advanced glycation endproducts: what is their relevance to diabetic complications? Diabetes Obes Metab 2007;9:233-45
PubMed Web of Science ®Google Scholar
Lo TW, Westwood ME, McLellan AC, et al. Binding and modifications of protein by methylglyoxal under physiologic conditions: a kinetic and mechanistic study with N-e-acetylarginine, N-e-acetylcysteine and bovine serum albumin. J Biol Chem 1994;269:32299-305
PubMed Web of Science ®Google Scholar
Ahmed MV, Thorpe SR, Baynes JW. Identification of N-e-carboxymethyllysine as a degradation product of fructosyl lysine in glycated protein. J Biol Chem 1986;261:4889-94
PubMed Web of Science ®Google Scholar
Rasheed Z, Ali R. Reactive oxygen species damaged human serum albumin in patients with type 1 diabetes mellitus: biochemical and immunological studies. Life Sci 2006;79:2380-8
Google Scholar
Kurien B T, Hensley K, Bachamn M, et al. Oxidatively modified autoantigens in autoimmune disease. Free Radic Biol Med 2006;15:549-56
Web of Science ®Google Scholar
Wilson PW, Ben-Yehuda O, McNamara J, et al. Autoantibodies to oxidized LDL and cardiovascular risk: the Framinghan Offspring study. Atherosclerosis 2006;189:364-8
PubMedGoogle Scholar
Ahmed E, Trifunovic J, Stegmavr, et al. Autoantibodies against modified LDL do not constitute a risk factor for stroke: a nested case-control study. Stroke 1999;30:2541-6
PubMed Web of Science ®Google Scholar
Luoma JS, Karcinen A, Navanen O, et al. Autoantibodies against LDL are associated with severe chest pain attacks in patients with coronary heart disease. Free Radic Biol Med 2205;39:1660-5
Google Scholar
Lopez LR, Hurley BL, Simpson DF, et al. Oxidized low-density lipoprotein/β2-glycoprotein I complexes and autoantibodies in patients with type 2 diabetes mellitus. Ann NY Acad Sci 2005;105:97-103
Google Scholar
Malickova K, Skrha J, Janathkova I, et al. Antibodies against low density oxidized lipoprotein in type 2 diabetics. Epidemiol Microbiol Immunol 2004;53:131-5
Google Scholar
Schmidt AM, Yan SD, Yan SF, et al. RAGE: a multiligand receptor serving as a progression factor amplifying the immune/inflammatory response. J Clin Invest 2001;108:949-55
PubMed Web of Science ®Google Scholar
Sugaya K, Fukagawa T, Matsumoto K, et al. Three genes in human MHC class III region near the junction with the class II gene for receptors of advanced glycosylation end products, PBX2 homebox gene and a notch homolog human counterpart of mouse mammary tumor gene int-3. Genomics 1994;23:408-19
PubMed Web of Science ®Google Scholar
Bierhaus A, Illmer M, Luther T, et al. Advanced glycation end products (AGE)-mediated of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation 1997;96:2262-71
PubMed Web of Science ®Google Scholar
Yan SD, Schmidt AM, Anderson GM, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptor/binding protein. J Biol Chem 1994;269:9889-97
PubMed Web of Science ®Google Scholar
Schiekofer S, Andrassy M, Chen J, et al. Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK and nuclear factor-κB in PBMNCs. Diabetes 2003;52:621-33
PubMed Web of Science ®Google Scholar
Taguchi A, Blood DC, Del Toro G, et al. Blockade of RAGE-amphoterin signaling suppresses tumor growth and metastases. Nature 2000;405:354-60
PubMed Web of Science ®Google Scholar
Goova MT, Li J, Kislinger T, et al. Blockade of receptor for advanced glycation end-products restores effectives wound healing in diabetic mice. Am J Pathol 2001;159:513-25
PubMed Web of Science ®Google Scholar
Thallas-Bonke V, Thorpe SR, Coughlan MT, et al. Inhibition of NADPH oxidase prevents advanced glycation end products-mediated damage in diabetic nephropathy through a protein kinase C-α-dependent pathway. Diabetes 2008;57:460-9
PubMed Web of Science ®Google Scholar
Tan AL, Forbes JM, Cooper ME. AGE, RAGE and ROS in diabetic nephropathy. Semin Nephrol 2007;27:130-43
PubMed Web of Science ®Google Scholar
Coughlan MT, Cooper ME, Forbes JM. Renal microvascular injury in diabetes: RAGE and redox signalling. Antioxid Redox Signal 2007;9:331-42
PubMedGoogle Scholar
Thomas MC, Forbes JM, Cooper ME. Advanced glycation end products and diabetic nephropathy. Am J Ther 2005;12:562-672
PubMedGoogle Scholar
Coughlan MT, Cooper ME, Forbes JM. Can advanced glycation end product inhibitors modulate more than one pathway to enhance renoprotection in diabetes? Ann NY Acad Sci 2005;1043:750-8
PubMed Web of Science ®Google Scholar
Soro-Paavonen, Forbes JM. Novel therapeutics for diabetic micro and macrovascular complications. Curr Med Chem 2006;13:1777-88
PubMed Web of Science ®Google Scholar
Stitt AW, Bucala R, Vlassara H, et al. Atherogenesis and advanced glycation: promotion, progression and prevention. Ann NY Acad Sci 1997;811:115-27
PubMed Web of Science ®Google Scholar
Buciarelli LG, Wendt T, Rong L, et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 2002;59:1117-28
PubMedGoogle Scholar
Wautier JL, Zoukourian C, Chappey O, et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 1996;97:238-43
PubMed Web of Science ®Google Scholar
Park L, Raman KG, Lee KJ, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998;4:1025-31
PubMed Web of Science ®Google Scholar
Kislinger T, Tanji N, Wendt T, et al. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vase Biol 2001;21:905-10
PubMed Web of Science ®Google Scholar
Buciarelli LG, Wendt T, Qu W, et al. RAGE blockade stabilizes established atherosclerosis apolipoprotein in E-null mice. Circulation 2002;106:2827-35
PubMedGoogle Scholar
Wendt T, Buciarelli L, Qu W, et al. Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complication in diabetes. Curr Atheroscler Rep 2002;24:228-37
Google Scholar
Yonekura H, Yamamoto Y, Sakurai S, et al. Novel splice variant of RAGE expressed in human vascular endothelial cells and pericytes and their putative roles in diabetes-induced vascular injury. Biochem J 2003;370:1097-109
PubMed Web of Science ®Google Scholar
Cheng C, Tsuneyama K, Kominami R, et al. Expression profiling of esRAGE in human organs. Mod Pathol 2005;18:1385-96
PubMed Web of Science ®Google Scholar
Devangelio E, Santilli F, Formoso G, et al. sRAGE in type 2 diabetes: association with oxidative stress. Free Radic Biol Med 2007;43:511-8
PubMed Web of Science ®Google Scholar
Forbes J, Thorpe S, Thallas-Bonke V, et al. Modulation of sRAGE by ACE-1 inhibition in diabetic nephropathy. J Am Soc Nephrol 2005;16:2363-72
PubMed Web of Science ®Google Scholar
Lin L. RAGE on the Toll Road? Cell Mol Immunol 2006;3:351-8
PubMed Web of Science ®Google Scholar
Mullick AE, Tobias PS, Curtiss LK. Toll-like receptors and atherosclerosis: key contributors in disease and health? Immunol Res 2006;34:193-209
PubMed Web of Science ®Google Scholar
Hanson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006;6:508-19
PubMedGoogle Scholar
Liliensiek B, Weigand MA, Bierhaus A, et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 2004;113:1641-50
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

From hyperglycemia to AGE-RAGE interaction on the cell surface: A dangerous metabolic route for diabetic patients

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

From hyperglycemia to AGE-RAGE interaction on the cell surface: A dangerous metabolic route for diabetic patients

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date